3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
14
Ovarian Neoplasms
6
Neoplasms
5
Liposarcoma
5
Leiomyosarcoma
5
Liposarcoma, Myxoid
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Ichthyosis, X-Linked
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Solitary Fibrous Tumors
1
Soft Tissue Neoplasms
1
Skin Diseases
1
Sarcoma, Synovial
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Alveolar Soft Part
1
Recurrent High Grade Meningioma
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Mesothelioma
1
Malignant mesenchymal tumor
1
Interventions
Gemcitabine
5
Nivolumab
3
Irinotecan
3
Ipilimumab
3
Docetaxel
3
Cyclophosphamide
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
pegfilgrastim
2
Vincristine
2
Temozolomide
2
Ibandronic Acid
2
Doxorubicin
2
CTLA-4 Antigen
2
spartalizumab
1
saracatinib
1
samarium Sm-153 lexidronam
1
pembrolizumab
1
palbociclib
1
liposomal doxorubicin
1
fludarabine
1
anlotinib
1
angiotensin I (1-7)
1
aldesleukin
1
Zoledronic Acid
1
Trabectedin
1
Topotecan
1
Taxes
1
Sunitinib
1
Samarium
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bone Neoplasms
×
Trabectedin
×
Clear all
NCT05131386
2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
85 enrolled